ONCOBREAST-TEST is a diagnostic and therapeutic procedure that is part of the comprehensive care of a patient with breast cancer.: Chemosensitivity of cancer cells was assessed using the MTT test, morphological assessment of cells, LDH activity in the culture medium, and flow cytometry technique (apoptosis, proliferation, CD24, CD44, GATA3, cytokeratin, Ki-67). Diagnostic tools included panels of simple tests which could be used to accurately predict the chemosensitivity of tumor cells previously isolated from a patient, even before actual chemotherapy. The proposed procedure allows for a simple (based on MTT results, cell morphology, LDH concentration), minimally invasive, quick, and accurate assessment of the sensitivity of breast cancer cells to the drugs used and, to select the most effective treatment plan as part of personalized therapy. In a patient with NOS G3, the most promising therapy will be docetaxel with cyclophosphamide and in the case of a patient with NOS G1, paclitaxel alone and in combination with trastuzumab. The implementation of such a procedure would undoubtedly increase the effectiveness of chemotherapy, reduce side effects by excluding drugs that are ineffective before using them, protect the patient’s health, and shorten the treatment time, bringing economic and social benefits.
ONCOBREAST-TEST是一种诊断与治疗流程，属于乳腺癌患者综合管理的一部分。该流程通过MTT实验、细胞形态学评估、培养基中乳酸脱氢酶活性检测以及流式细胞术（检测细胞凋亡、增殖及CD24、CD44、GATA3、细胞角蛋白、Ki-67表达）评估癌细胞的化疗敏感性。其诊断工具采用一组简易检测组合，可在实际化疗开始前，利用从患者体内分离的肿瘤细胞准确预测其化疗敏感性。该方案能够通过简便（基于MTT结果、细胞形态和LDH浓度）、微创、快速且精准的方式，评估乳腺癌细胞对所用药物的敏感性，从而为个体化治疗选择最有效的方案。对于NOS G3型患者，多西他赛联合环磷酰胺是最具前景的治疗方案；而对于NOS G1型患者，紫杉醇单药或联合曲妥珠单抗治疗效果更佳。实施该流程将显著提升化疗疗效，通过提前排除无效药物降低副作用，保护患者健康，缩短治疗周期，从而产生经济与社会双重效益。
肿瘤(癌症)患者之家